{
    "clinical_study": {
        "@rank": "156569", 
        "acronym": "IPF", 
        "arm_group": [
            {
                "arm_group_label": "Placebo (without active ingredient)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo will be taken  two tablets  3 times a day during the whole study process."
            }, 
            {
                "arm_group_label": "Pirfenidone\uff08200mg\uff09", 
                "arm_group_type": "Experimental", 
                "description": "Pirfenidone\uff08200mg\uff09tablets will be taken two tablets 3 times a day during the whole study process."
            }
        ], 
        "brief_summary": {
            "textblock": "Pirfenidone as anti-fibrosis drug developed in recent years demonstrated the potential anti-\n      fibrotic effect, but so far there were no domestic studies  about pirfenidone's efficacy and\n      safety evaluation in china. The aim of this study was to evaluate the efficacy and safety of\n      pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) through the observation of\n      a large sample of clinical cases."
        }, 
        "brief_title": "Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Idiopathic Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis", 
                "Idiopathic Pulmonary Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of this study was to evaluate the efficacy and safety of pirfenidone in patients\n      with idiopathic pulmonary fibrosis (IPF) through the observation of a large sample of\n      clinical cases. During the observation, study visits will occur at the end of 12w, 24w, 36w,\n      48w.all participants will be required to check the various efficacy and safety indicators."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent signed;\n\n          2. Age \u226475 years;\n\n          3. Clinically or multidisciplinary diagnosed idiopathic pulmonary fibrosis(see 2011\n             guidance );\n\n          4. Resting state PaO2\u226550mg, FVC%\u226545% normal predicted value and DLCO\u226530% normal\n             predicted value.\n\n        Exclusion Criteria:\n\n          1. Allergic to pirfenidone;\n\n          2. Patients with serious Significant pulmonary infection need anti-infection treatment;\n\n          3. Patients who has taken interferon, penicillamine or other agents for the treatment of\n             IPF;\n\n          4. Patients who has taken prednisone(\u226550mg) or other glucocorticoid in the past 1 month;\n\n          5. Patients who has taken immunosuppressants  in the past 1 month;\n\n          6. Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3\n             months;\n\n          7. Patients with malignant tumor in the past 5 years;\n\n          8. Participated in other clinical trials in the past 3 months;\n\n          9. Patients with serious heart disease(NYHA class \u2162-\u2163), liver disease(ALT or AST 2 times\n             above the upper level of normal value range), kidney disease(Cr above the upper level\n             of normal value range);\n\n         10. Pregnant or lactating women;\n\n         11. The investigator assessed as inappropriate to participate in this clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136992", 
            "org_study_id": "SPH01312"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo (without active ingredient)", 
                    "Pirfenidone\uff08200mg\uff09"
                ], 
                "description": "Pirfenidone\uff08200mg\uff09tablets will be taken two tablets 3 times a day during the whole study process.", 
                "intervention_name": "Pirfenidone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo (without active ingredient)", 
                    "Pirfenidone\uff08200mg\uff09"
                ], 
                "description": "placebo will be taken two tablets 3 times a day during the whole study process", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pirfenidone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis", 
        "overall_official": {
            "affiliation": "Shanghai Pulmonary Hospital , Tongji University", 
            "last_name": "Huiping Li", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "to evaluate changes in FVC  from baseline to 12 weeks /24 weeks/36 weeks/48 weeks", 
            "measure": "Changes in forced vital capacity (FVC)", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136992"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Pulmonary Hospital, Shanghai, China", 
            "investigator_full_name": "Huiping Li", 
            "investigator_title": "Huiping Li", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Lung function will be measured as improved/stabilized/exacerbated from baseline to 12 weeks/24 weeks/36 weeks/48 weeks", 
                "measure": "changes in lung function (including Forced expiratory volume in one second (FEV1) and The differences of diffusing capacity of the lung for carbon monoxide (DLco) )", 
                "safety_issue": "No", 
                "time_frame": "48week"
            }, 
            {
                "description": "Changes in 6 minute walk distance (6MWD) and  from baseline to 12/24/36/48weeks", 
                "measure": "Changes in 6 minute walk distance (6MWD)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Life quality will be assessed as improved if SGRQ single or total score increased >4% when completing the trial; Life quality will be assessed as stabilized if SGRQ single or total score changes within the range of 4% when completing the trial; Life quality will be assessed as exacerbated if SGRQ single or total score decreased >4% when completing the trial.", 
                "measure": "Life quality: assessed by St. George respiratory questionnaire (SGRQ).", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "to measure  rating dyspnea according by Medi Medical Research Center(MMRC)", 
                "measure": "Dyspnea score according by Modified Medical Research Center(MMRC)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "Shanghai Pulmonary Hospital, Shanghai, China", 
        "sponsors": {
            "collaborator": {
                "agency": "Nanjing Chia-tai Tianqing Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Shanghai Pulmonary Hospital, Shanghai, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}